Onkozentrum Dresden/Freiberg
Industry / private company
Location:
Dresden,
Germany (DE)
ISNI: -
ROR: https://ror.org/05090cn78
Treatment response lowers tumor symptom burden in recurrent and/or metastatic head and neck cancer (2020)
Hecht M, Hahn D, Wolber P, Hautmann MG, Reichert D, Weniger S, Belka C, et al.
Journal article
Single cycle induction treatment with cisplatin/docetaxel plus durvalumab/tremelimumab in stage III-IVB head and neck squamous cell cancer (CheckRad-CD8 trial) (2019)
Hecht M, Gostian AO, Eckstein M, Rutzner S, Von Der Gruen J, Illmer T, Hautmann MG, et al.
Conference contribution
Advanced renal cell carcinoma: First results from the prospective research platform CARAT for patients with mRCC in Germany (2019)
Goebell P, Mueller L, Gruellich C, Reichert D, Boegemann M, Doerfel S, Von Der Heyde E, et al.
Conference contribution
Cetuximab in combination with platinum-based chemotherapy or radiotherapy in patients with recurrent and/or metastatic SSCHN in clinical routine: Updated interim results of the prospective SOCCER study (2018)
Hecht M, Hahn D, Wolber P, Hautmann M, Reichert D, Weniger J, Belka C, et al.
Conference contribution
Cetuximab in combination with platinum-based chemotherapy or radiotherapy in recurent and/or metastatic SCCHN in a non-selected patient cohort (interim analysis of the phase IV SOCCER trial) (2016)
Hecht M, Hahn D, Beutner D, Reichert D, Goehler T, Wurm R, Welslau M, et al.
Conference contribution
Cetuximab in combination with platinum-based chemotherapy or radiotherapy in recurent and/or metastatic SCCHN in a non-selected patient cohort (interim analysis of the phase IV SOCCER trial) (2016)
Hecht M, Hahn D, Beutner D, Reichert D, Goehler T, Wurm R, Welslau M, et al.
Conference contribution